Completed PHASE2 INTERVENTIONAL 1-arm NCT00890656

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Phase II Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Sponsor: Enzon Pharmaceuticals, Inc.

Interventions Ara-C Cyclophosphamide (CTX) Decadron Doxorubicin G-CSF Methotrexate (MTX) Pegaspargase Vincristine

Updated 7 times since 2017 Last updated: Feb 17, 2012 Started: Jun 30, 2003 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Acute Lymphoblastic Leukemia, this trial is completed. The trial is conducted by Enzon Pharmaceuticals, Inc. and has accumulated 7 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enzon Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States